Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

28 juin 2016 08h39 HE | Source: XBiotech, Inc

XBiotech Signs Agreement With Megapharm To Market Xilonix™ In Israel

AUSTIN, Texas, June 28, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human™ antibody therapies, today announced that it has entered into an exclusive...
08 juin 2016 11h11 HE | Source: XBiotech, Inc

XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Company’s Extensive Product Portfolio

AUSTIN, Texas, June 08, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), the developer of True Human™ therapeutic antibodies, announced today that Trey Benson has joined the company as Commercial...
24 mai 2016 08h00 HE | Source: XBiotech Inc.

XBiotech to Present Positive Preliminary Survival Data on Xilonix™ at the 18th European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer

First Time Pivotal Phase III Xilonix Data to be Unveiled at Major Scientific Congress, Including Positive Preliminary Overall Mean Survival Data for RespondersDeveloped Specifically to Treat...
18 mai 2016 08h00 HE | Source: XBiotech Inc.

XBiotech Provides First Quarter 2016 Corporate and Clinical Update

Conference Call and Webcast today, May 18 at 8:30 a.m. ET RECENT HIGHLIGHTS European Medicines Agency accepts Marketing Authorization Application for Xilonix™ in colorectal cancer and...
16 mai 2016 08h00 HE | Source: XBiotech Inc.

XBiotech Names Industry Veteran Dawn McCollough to Head Clinical Operations

AUSTIN, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), the developer of True Human™ therapeutic antibodies, today announced that Dawn McCollough has joined the company as Vice...
11 mai 2016 08h00 HE | Source: XBiotech Inc.

XBiotech to Provide First Quarter 2016 Business Update on May 18

AUSTIN, Texas, May 11, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that it will host a live conference call and webcast...
03 mai 2016 08h00 HE | Source: XBiotech Inc.

XBiotech Appoints Amgen Veteran Scott Whitehurst as Chief Financial Officer

AUSTIN, Texas, May 03, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced the appointment of Scott Whitehurst as Chief Financial...
19 avr. 2016 08h00 HE | Source: XBiotech Inc.

XBiotech to Present Pivotal Phase 3 Data on Xilonix™ at European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer

First Time Pivotal Phase 3 Xilonix™ Data To Be Unveiled at Major Scientific CongressDeveloped Specifically to Treat Advanced Cancer, Xilonix™ is First Antibody Therapy to Neutralize Biological...
04 avr. 2016 03h00 HE | Source: XBiotech Inc.

European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix™, XBiotech’s True Human™ Therapeutic Antibody Treatment for Advanced Colorectal Cancer

Xilonix poised to be a first-in-class, True Human monoclonal (IgG1k) antibodyFirst to neutralize biological activity of interleukin-1α (IL-1a), developed specifically to treat advanced cancerEMA...
28 mars 2016 08h00 HE | Source: XBiotech Inc.

XBiotech Advances to Phase II Portion of Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus

AUSTIN, Texas, March 28, 2016 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, announced today that the last patient in the Phase 1 portion of its...

Page précédente